Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Folsmart is a targeted liposomal formulation of the small molecule antimetabolite methotrexate, developed by SOLFARCOS for the treatment of rheumatoid arthritis. The drug utilizes a targeted liposomal delivery system designed to selectively accumulate in inflamed synovial tissues, thereby increasing local therapeutic concentrations while minimizing the systemic toxicity typically associated with conventional methotrexate therapy. Methotrexate acts as a competitive inhibitor of the enzyme dihydrofolate reductase (DHFR), which is essential for the synthesis of purines and pyrimidines. By disrupting DNA synthesis and cell proliferation, Folsmart aims to suppress the immune cell activity that drives joint inflammation and destruction in patients with rheumatoid arthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Folsmart.